LABATEC PHARMA ANNOUNCES AN EXCLUSIVE LICENSING AGREEMENT SIGNED WITH AFT PHARMACEUTICALS, TO COMMERCIALISE MAXIGESIC IV®, IN SWITZERLAND
Geneva, March 27, 2023 – Labatec Pharma SA (Labatec) signed a new licensing agreement with AFT Pharmaceuticals (NZX.AFT, ASX.AFP), for the exclusive rights to commercialise Maxigesic IV® in Switzerland, a treatment for mild to moderate pain for use post-operatively in hospitals when patients cannot take a medicine orally.
In the terms of the agreement, Labatec will take care of all commercial activities related to Maxigesic IV® including sales, marketing, medical affairs, pricing, and reimbursement while AFT will be responsible for supplying the drug to Labatec.
Faisal Darwazeh, CEO of Labatec “We are broadening our hospital portfolio with this novel essential medicine for our patients in Switzerland. Maxigesic IV® will strengthen our innovative medicine portfolio, enhancing Labatec’s established role as a trusted partner to Swiss hospitals.”
Both companies are aiming for registration and launch of this innovative intravenous pain relief medicine in the next 12 to 18 months in Switzerland.
For further information please contact:
Labatec Pharma SA
Business Development Team
Email: partnering@labatec.com
Tel: +41 22 785 95 00 (Head Office)
For media enquiries please contact:
Labatec Pharma SA
Head of Press & Communications
Email: press@labatec.com
Tel: +41 22 785 95 00 (Head Office)
About Labatec
A Swiss based privately owned pharmaceutical company, based in Meyrin (Geneva). Labatec develops and markets medicines that contribute to improving patients’ quality of life. Labatec is a leading licensing partner in the specialty and innovative medicines segments, across the Swiss and MENA markets.
Labatec’s extensive portfolio includes more than 100 high-quality products, manufactured in Europe and Canada, and supplied to 14 countries comprising Switzerland, Austria, the Middle East and North Africa. Labatec is a recognized partner of choice for hospitals (anti-infectious, anesthetic, antiemetic and oncological products) and has an established retail presence in the therapeutic categories of osteoporosis, muscle relaxants, women’s health and ophthalmology. For more information about the company, visit our website https://www.labatecpharma.com/
About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. AFT is present in Australia, New Zealand and in certain Southeast Asian markets, and through local partners in over 125 countries. www.aftpharm.com
